Search tips
Search criteria 


Logo of aicSpringerOpen.comThis journalSubmit a manuscriptRegisterSpringerOpen.comAnnals of Intensive Care
Ann Intensive Care. 2012; 2: 33.
Published online Jul 26, 2012. doi:  10.1186/2110-5820-2-33
PMCID: PMC3475105
Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials
Ary Serpa Neto,corresponding author1 Victor Galvão Moura Pereira,1 Daniel Crepaldi Espósito,1 Maria Cecília Toledo Damasceno,1 and Marcus J Schultz2
1Medical Intensive Care Unit, ABC Medical School (FMABC), Av. Lauro Gomes, Santo André, 2000, Brazil
2Department of Intensive Care Medicine & Laboratory of Experimental Intensive Care and Anesthesiology; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
corresponding authorCorresponding author.
Ary Serpa Neto: aryserpa/at/; Victor Galvão Moura Pereira: victorpereira33/at/; Daniel Crepaldi Espósito: dr.daniel/at/; Maria Cecília Toledo Damasceno: damasceno/at/; Marcus J Schultz: marcus.j.schultz/at/
Received April 29, 2012; Accepted July 4, 2012.
Acute respiratory distress syndrome (ARDS) is a potentially fatal disease with high mortality. Our aim was to summarize the current evidence for use of neuromuscular blocking agents (NMBA) in the early phase of ARDS.
Systematic review and meta-analysis of publications between 1966 and 2012. The Medline and CENTRAL databases were searched for studies on NMBA in patients with ARDS. The meta-analysis was limited to: 1) randomized controlled trials; 02) adult human patients with ARDS or acute lung injury; and 03) use of any NMBA in one arm of the study compared with another arm without NMBA. The outcomes assessed were: overall mortality, ventilator-free days, time of mechanical ventilation, adverse events, changes in gas exchange, in ventilator settings, and in respiratory mechanics.
Three randomized controlled trials covering 431 participants were included. Patients treated with NMBA showed less mortality (Risk ratio, 0.71 [95 % CI, 0.55 – 0.90]; number needed to treat, 1 – 7), more ventilator free days at day 28 (p = 0.020), higher PaO2 to FiO2 ratios (p = 0.004), and less barotraumas (p = 0.030). The incidence of critical illness neuromyopathy was similar (p = 0.540).
The use of NMBA in the early phase of ARDS improves outcome.
Keywords: ARDS, Neuromuscular blocking agents, Meta-analysis, Review
Articles from Annals of Intensive Care are provided here courtesy of